Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: 15 | Rare Historical Photos

Analyzing GSK's Short Interest

GSK's (NYSE:GSK) short percent of float has fallen 17.24% since its last report. The company recently reported that it has 6.02 million shares sold short, which is 0.24% of all regular shares that are available for trading.

Benzinga · Jun 15, 2022

Antibiotic Makers Adopt Their Own Environmental Safeguard Standards

The AMR Industry Alliance, a life-sciences coalition set up to provide sustainable solutions to curb antimicrobial resistance (AMR), is adopting its standards limiting toxic emissions. The Alliance published its Antibiotic Manufacturing Standard: Minimizing the risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from manufacturing human antibiotics. The…

Benzinga · Jun 15, 2022

Morning Brief: Top Financial Stories Dominating on Friday, June 10

Reuters Rebranded McDonald’s Restaurants To Reopen In Russia

Benzinga · Jun 10, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

GSK Shows Positive Pivotal Phase III Data For Its RSV Vaccine Candidate

GSK plc (NYSE:GSK) intends to engage with regulators immediately after reporting positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial, it anticipates regulatory submissions in the second half of 2022. AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate…

Benzinga · Jun 10, 2022

Why the malaria vaccine took 35 years

Malaria's complex biology played a role in the delay, but experts say there was also a lack of urgency and funding

Salon · Jun 6, 2022

GSK Confirms Consumer Healthcare Unit Spin-off: What Investors Should Know

Close on the heels of an M&A deal, GlaxoSmithKline plc (NYSE: GSK) confirmed the spin-off of the consumer healthcare business it jointly owns with U.S. pharma giant Pfizer, Inc.

Benzinga · Jun 1, 2022

Morning Brief: Top Financial Stories Dominating on Wednesday, June 1

Reuters Redbird Capital Buys Italian Football Club AC Milan

Benzinga · Jun 1, 2022

Read news from The Economist, FT, and more,
with one subscription

Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off

Pfizer Inc. (NYSE:PFE) intends to sell its 32% investment in Haleon, a consumer health joint venture with GSK plc (NYSE:GSK), after the business is spun out as an independent listed company in July, reported Reuters. Pfizer had previously indicated that it might seek to sell its stake in Haleon, a consumer health company and…

Benzinga · Jun 1, 2022

Unilever Jumps After Nelson Peltz Joins Board

Unilever plc (NYSE: UL) shares traded higher by 8% on Tuesday after the company announced activist investor Nelson Peltz is joining the company's board of directors.

Benzinga · May 31, 2022

GSK strikes deal to buy US vaccine firm Affinivax

It comes as the UK pharmaceutical business seeks to bolster its vaccine operation as part of a shake-up of its portfolio.

The Independent UK · May 31, 2022

GSK looking to invest more in Hyderabad

KTR holds discussions with Global R&D Head of GSK Consumer Health in London

The Hindu · May 19, 2022

3 Healthcare Stocks That Pay Dominant Dividends

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure, and numerous medical advancements. So, we think it could be wise to invest in fundamentally sound healthcare stocks Gilead (GILD), Takeda (TAK), and GlaxoSmithKline (GSK).…

StockNews.com · May 16, 2022

ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT

Benzinga · May 16, 2022

GlaxoSmithKline: Dividend Insights

Wednesday marks the last chance for investors to receive the next dividend payout from GlaxoSmithKline (NYSE:GSK).

Benzinga · May 16, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK · May 11, 2022

Hundreds of organisations breached patient data rules, reveals BMJ

Drug firms, private healthcare providers and universities among those that may be failing to protect confidentiality, says report

The Guardian - UK · May 10, 2022

Boots, Superdrug and other chemists report hay fever pill shortages

GlaxoSmithKline blames shortage of key ingredient for lack of Piriton and Piriteze tablets

StockNews.com · May 6, 2022

3 High-Yield Dividend Stocks to Buy in May: GlaxoSmithKline, A.P. Moeller-Maersk, and ENI

With the latest federal interest rate hike and the possibility of further monetary policy tightening, market indices have been going haywire. Because volatility is expected to persist, with experts fearing the economy will slip into recession, we think it could be wise to bet on high dividend-yielding stocks GlaxoSmithKline (GSK),…

Benzinga · Apr 27, 2022

GlaxoSmithKline Clocks 32% Topline Growth Buoyed By COVID-19 Therapy, Shingrix Vaccine

GlaxoSmithKline Plc's (NYSE:GSK) Q1 turnover reached £9.78 billion, up 32% Y/Y on actual exchange rate AER and constant exchange rate CER basis. Specialty Medicines turnover was £3.13 billion, up 98% AER, 97% CER (+16% AER, 15% CER excluding Xevudy), driven by consistent growth in all therapy areas, including sales of Xevudy. Sales…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Apr 27, 2022

Recap: GlaxoSmithKline Q1 Earnings

GlaxoSmithKline (NYSE:GSK) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · Apr 26, 2022

GlaxoSmithKline's Earnings Outlook

GlaxoSmithKline (NYSE:GSK) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that GlaxoSmithKline will report an earnings per share (EPS) of $0.76.

Benzinga · Apr 21, 2022

The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · Apr 13, 2022

Sierra Oncology Stock Is Soaring: Here's Why

Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an a

Evening Standard · Apr 13, 2022

GSK buys US-based cancer specialist Sierra Oncology for $1.9 billion

Deal is in step with GSK’s strategy of building a strong portfolio of new specialty medicines and vaccines

Benzinga · Apr 13, 2022

GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal

GlaxoSmithKline plc (NYSE:GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ:SRRA) for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion). Sierra's momelotinib complements GSK's Blenrep (belantamab mafodotin), building on GSK's commercial and medical expertise in hematology. If momelotinib is approved, GSK expects momelotinib will contribute to GSK's growing…

Benzinga · Apr 11, 2022

Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029

Germany has signed a contract with CureVac BV (NASDAQ:CVAC) and its partner GlaxoSmithKline plc (NYSE:GSK) for domestically produced mRNA vaccines to bolster supplies for pandemic preparedness. The five-year contract allows for the production of up to 80 million doses at short notice until 2029, CureVac said, adding that those doses could be for the remainder of…

1 … 14 15 16 17

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations